Jefferies Starts Lion Biotechnologies (LBIO) at Buy

Jefferies initiates coverage on Lion Biotechnologies (OTC: LBIO) with a Buy rating and a price target of $12.00.

Analyst Biren Amin comments, "LBIO appears poised to be the leading player in tumor-infiltrating lymphocytes (TILs), and is one of the exciting developments in immuno-oncology. LBIO has significant potential based on clinical data with LN-144 observing highly robust and durable responses in refractory metastatic melanoma, supporting a highly favorable outlook for the pivotal PIII trial beginning ~YE'15."

For an analyst ratings summary and ratings history on Lion Biotechnologies click here. For more ratings news on Lion Biotechnologies click here.

Shares of Lion Biotechnologies closed at $8.17 yesterday.

You May Also Be Interested In

• Northland Starts Bitfarms Ltd. (BITF) at Outperform
• Weatherford International plc (WFRD) PT Raised to $184 at Piper Sandler
• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition